The global gout therapeutics market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factor contributing to the growth of the market include the increasing prevalence of gout across the globe. According to the National Center for Biotechnology Information (NCBI), an estimated 1 to 2% of the population is affected by gout globally. Additionally, men are more likely to get it than women with an estimated five times more in men. Furthermore, gout mostly occurs in men aged 40 and above while it usually only affects women after menopause. Hence, the increasing prevalence of gout is driving the demand for gout treatment, which in turn is driving the growth of the market.

Moreover, the market is segmented into drug class and application. Based on drug class, the market is sub-segmented into antihyperuricemic agents (Urate-Lowering Drugs), non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, colchicine and others. Based on application, the market is sub-segmented into acute gout and chronic gout. NSAIDs hold a prominent share in the market due to their low cost compared to other pharmacological classes coupled with their ability to relieve pain in the case of a severe attack.

Some major key players in the market include Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in April 2021, HemoShear Therapeutics, Inc. has collaborated with Horizon Therapeutics plc to identify a second drug for the treatment of gout.  

Market Coverage

    • The market number available for – 2020-2027

    • Base year- 2020

    • Forecast period- 2021-2027

    • Segment Covered- 

o By Drug Class

o By Application

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

    • Competitive Landscape- Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd., among others.

Key questions addressed by the report

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How players are addressing challenges to sustain growth?

    • Where is the investment opportunity?

Global Gout Therapeutics Market Report by Segment

By Drug Class

    • Antihyperuricemic Agents (Urate-Lowering Drugs)

    • Non-steroidal Anti-inflammatory Drugs (NSAIDs)

    • Corticosteroids

    • Colchicine

    • Others 

By Application 

    • Acute Gout

    • Chronic Gout

Global Gout Therapeutics Market Report by Region

North America

    • United States

    • Canada

Europe

    • UK

    • Germany

    • Italy

    • Spain

    • France

    • Rest of Europe 

Asia-Pacific

    • China

    • India

    • Japan

    • South Korea

    • Rest of Asia-Pacific 

Rest of the World

    • Latin America 

    • Middle East & Africa